Antitissue transglutaminase antibodies in acute coronary syndrome: an alert signal of myocardial tissue lesion?

Background and aim.  Antitransglutaminase, previously considered identical to antiendomysial in coeliac sprue (CS), have been reported in end‐stage heart failure. To clarify the above‐mentioned data, we evaluated these antibodies in a cohort of cardiological patients with respect to troponin I, creatine kinase (CK), MB fraction creatine kinase (CK‐MB mass) and myoglobin.

[1]  D. Sane,et al.  Roles of transglutaminases in cardiac and vascular diseases. , 2007, Frontiers in bioscience : a journal and virtual library.

[2]  R. Nisihara,et al.  Celiac Disease Prevalence in Brazilian Dilated Cardiomyopathy Patients , 2006, Digestive Diseases and Sciences.

[3]  J. Hang,et al.  The role of tissue transglutaminase in cell-matrix interactions. , 2006, Frontiers in bioscience : a journal and virtual library.

[4]  F. Pansini,et al.  Transglutaminase and vascular biology: physiopathologic implications and perspectives for therapeutic interventions. , 2005, Current medicinal chemistry.

[5]  I. Hill.  What are the sensitivity and specificity of serologic tests for celiac disease? Do sensitivity and specificity vary in different populations? , 2005, Gastroenterology.

[6]  C. Rodolfo,et al.  Type 2 transglutaminase and cell death. , 2005, Progress in experimental tumor research.

[7]  J. Stulík,et al.  Identification of new celiac disease autoantigens using proteomic analysis , 2003, Proteomics.

[8]  I. Korponay-Szabó,et al.  Missing endomysial and reticulin binding of coeliac antibodies in transglutaminase 2 knockout tissues , 2003, Gut.

[9]  M. Bardella,et al.  Tissue transglutaminase antibodies in patients with end-stage heart failure , 2002, American Journal of Gastroenterology.

[10]  Mauro Piacentini,et al.  Transglutaminase 2: an enigmatic enzyme with diverse functions. , 2002, Trends in biochemical sciences.

[11]  M. Piacentini,et al.  Presence of anti-‘tissue’ transglutaminase antibodies in inflammatory intestinal diseases: an apoptosis-associated event? , 2001, Cell Death and Differentiation.

[12]  J S Alpert,et al.  Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. , 2000, Journal of the American College of Cardiology.

[13]  H. Uhlig,et al.  Evidence for existence of coeliac disease autoantigens apart from tissue transglutaminase , 2000, European journal of gastroenterology & hepatology.

[14]  Hugo A. Katus,et al.  Myocardial infarction redefined--a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. , 2000, European heart journal.

[15]  M. Curione,et al.  Prevalence of coeliac disease in idiopathic dilated cardiomyopathy , 1999, The Lancet.

[16]  Gilmour,et al.  Anti‐tissue transglutaminase, anti‐endomysium and anti‐R1‐reticulin autoantibodies—the antibody trinity of coeliac disease , 1999, Clinical and experimental immunology.

[17]  I. Korponay-Szabó,et al.  Tissue transglutaminase autoantibody enzyme-linked immunosorbent assay in detecting celiac disease. , 1998, Gastroenterology.

[18]  D. Schuppan,et al.  Identification of tissue transglutaminase as the autoantigen of celiac disease , 1997, Nature Medicine.

[19]  T. Mothes,et al.  Isolation of antigens recognized by coeliac disease autoantibodies and their use in enzyme immunoassay of endomysium and reticulin antibody‐positive human sera , 1996, Clinical and experimental immunology.

[20]  M. Mäki,et al.  Purification of Fibroblast-Derived Celiac Disease Autoantigen Molecules , 1993, Pediatric Research.